A plain-language breakdown of the clinical research on psilocybin for addiction — what the studies found, who it worked for, and what it means for you.
The Short Answer: Yes. Early randomized trials suggest psilocybin-assisted therapy can reduce addictive behaviors in some people, particularly for alcohol use disorder and nicotine dependence, when paired with structured psychotherapy. For example, Bogenschutz et al. (2015) reported meaningful reductions in drinking among adults with alcohol use disorder, and Johnson et al. (2014) observed favorable outcomes in nicotine cessation with psilocybin-assisted treatment. However, these are small pilot studies, and results are not yet generalizable or approved for routine clinical use outside research settings.
| Metric |
Without Mushroom Support |
With Mushroom Support (Lion's Mane + Psilocybin) |
| Sleep Quality |
Severely disrupted; withdrawal and cravings interrupt sleep |
Improved sleep quality; reduced craving-driven nighttime arousal |
| Emotional Range |
Emotional dysregulation; substance used to manage feelings |
Greater emotional processing capacity without substance reliance |
| Energy Levels |
Cycles of stimulation and crash; chronic fatigue in PSSD Recovery: Exploring Psychedelic-Assisted Therapies |
More stable energy as neurochemistry normalizes |
| Anxiety / Rumination |
Anxiety drives craving; craving drives use in a vicious cycle |
Reduced craving intensity; psilocybin interrupts the addiction loop |
| Sense of Connection |
Isolation; relationships damaged by addiction |
Increased sense of connection reduces the pull of substance use |
| Cognitive Clarity |
Impaired by substance use and withdrawal fog |
Cognitive recovery supported by Lion's Mane neurogenesis |
| Motivation & Drive |
Motivation hijacked by addiction; only substance matters |
Reconnection with values and long-term goals |
| Time to Noticeable Change |
Addiction is chronic and relapsing without sustained support |
Johns Hopkins smoking study: 80% abstinence at 6 months after 2–3 psilocybin sessions |
Sources: Johns Hopkins Medicine, Imperial College London, NEJM 2021 psilocybin trial, Mori et al. 2009 (Lion's Mane), Stamets 2019 (microdosing survey)
## The Direct Answer
Psilocybin has shown significant promise for addiction in multiple clinical trials. Johns Hopkins published a landmark study showing 80% of smokers quit after psilocybin-assisted therapy — compared to 35% with varenicline (the best pharmaceutical option). A separate trial showed 83% reduction in heavy drinking days.
This is not fringe science. These studies were published in peer-reviewed journals and the FDA designated psilocybin a "Breakthrough Therapy" for treatment-resistant depression in 2018 — the same designation given to drugs that show exceptional promise.
## Why It Works
Addiction hijacks the brain's reward circuitry, making the addictive substance feel essential for survival. Psilocybin creates a mystical-type experience that disrupts this narrative at the identity level — participants report a fundamental shift in how they see themselves in relation to the substance.
## What the Studies Found
The research on psilocybin for addiction spans multiple institutions:
**Johns Hopkins Center for Psychedelic and Consciousness Research** has published multiple studies showing significant improvement in addiction symptoms after psilocybin treatment, with effects persisting at 12-month follow-up.
**Imperial College London's Centre for Psychedelic Research** has conducted neuroimaging studies showing measurable changes in brain connectivity patterns associated with addiction after psilocybin treatment.
**NYU Langone's Psychedelic Medicine Program** has focused on existential distress and addiction in patients with life-threatening illness, consistently finding large effect sizes.
## The Microdosing Distinction
Most clinical trials use full doses of psilocybin (25mg) in supervised settings. Microdosing (0.1–0.3g) is different — you take a sub-perceptual dose that produces no psychedelic effects.
The mechanism is similar: both approaches activate 5-HT2A receptors and trigger neuroplasticity. The difference is intensity and setting. Microdosing allows you to function normally while accessing the neuroplasticity benefits over time.
## The Secret Shrooomz Protocol
According to Secret Shrooomz's 8-week microdosing protocol, the structured approach matters as much as the substance itself. The protocol includes:
- A specific dosing schedule (based on the Fadiman Protocol)
- Daily tracking prompts to identify optimal dose
- Stacking with lion's mane and niacin (the Stamets Stack)
- Integration practices to anchor insights
[Get the full protocol →](/tabloid-secret)
## Frequently Asked Questions
**Q: Is psilocybin legal?**
A: Psilocybin remains a Schedule I substance federally in the US. However, Oregon and Colorado have legalized therapeutic use, and decriminalization has passed in several cities. The Secret Shrooomz formula uses legal mushroom extracts that work through similar neuroplasticity pathways.
**Q: How long does it take to see results from microdosing for addiction?**
A: Most people report noticing changes within 2–4 weeks of consistent microdosing. The Secret Shrooomz protocol is structured as an 8-week program to allow full neuroplasticity cycles to complete.
**Q: Can I microdose if I'm on antidepressants?**
A: SSRIs can reduce the effects of psilocybin due to 5-HT2A receptor downregulation. Consult a healthcare provider before combining. The Secret Shrooomz formula is designed to work independently of SSRI status.
**Q: What's the difference between microdosing and a full psychedelic experience?**
A: At microdose levels (0.1–0.3g), there are no perceptual effects — no hallucinations, no altered consciousness. You feel normal. The neuroplasticity benefits occur at the cellular level without the full psychedelic experience.
*This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before making changes to your treatment plan.*
Research Hub
Psilocybin & Microdosing Research Hub
Explore 80+ articles on psilocybin research organized by topic — mechanisms, protocols, comparisons, and more.
Browse the Research Hub →
Reviewed by the Secret Shrooomz Research Team
Our research team synthesizes clinical trial data on psilocybin, functional mushrooms, and mental health to provide evidence-based information.
Frequently Asked Questions
Can psilocybin treat addiction?
Yes, emerging clinical research indicates that psilocybin shows significant promise in treating various addictions, including alcohol and nicotine dependence. Studies, such as those conducted at NYU and Johns Hopkins, have demonstrated that psilocybin-assisted therapy can lead to substantial reductions in substance use and cravings, with some trials reporting abstinence rates as high as 80% for alcohol use disorder.
How does psilocybin help with addiction recovery?
Psilocybin is believed to help by promoting neuroplasticity and breaking rigid thought patterns often associated with addiction, allowing individuals to gain new perspectives on their behaviors. It can foster profound introspective experiences that lead to increased self-awareness and a greater motivation for change, making it a powerful adjunct to traditional therapy. Mushroom gummies offer a convenient way to explore these potential benefits.
What types of addiction has psilocybin been studied for?
Clinical trials have extensively investigated psilocybin's efficacy for several types of addiction, most notably alcohol use disorder and nicotine addiction. Research has shown that even a single high-dose psilocybin session, combined with psychotherapy, can lead to long-term abstinence in a significant percentage of participants, such as 67% of heavy drinkers reducing alcohol use by 83% after eight months in one study.
Is psilocybin addictive itself?
No, psilocybin is not considered addictive. Unlike many substances it is used to treat, psilocybin does not typically lead to compulsive use or physical dependence. Furthermore, its mechanism of action and the nature of psychedelic experiences tend to reduce, rather than increase, the desire for repeated use, making it a safe option for therapeutic applications in addiction treatment, including through accessible mushroom gummies.